Ginkgo Bioworks Holdings Inc vs FuelCell Energy Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while FuelCell Energy Inc trades at $18.03 (market cap $1.47B). The key difference: FuelCell Energy Inc is the larger of the two by market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, FuelCell Energy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and FuelCell Energy Inc for 48 Days on average.
| DNA | FCEL | |
|---|---|---|
Market Cap | $763.64M | $1.47B |
Volume | 3,204,177 | 12,559,948 |
Sector | Health | Industrials |
52-Week High | $15.83 | $36.01 |
52-Week Low | $5.48 | $6.00 |
Typical Hold Time | 7 Days | 48 Days |
Enterprise Value | $865.59M | $1.05B |
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.00, up 13.34% today, with a bullish technical signal from moving averages. The company shows strong gross margins of 68.04% but remains unprofitable with a -219.6% net margin. Recent news includes a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnership expansions, though revenue declined to $132M in 2026.
DNA presents high risk with significant losses and cash burn, but analyst sentiment is divided with equal buy/sell ratings. Investment appeal hinges on future profitability from recent partnerships and government contracts, while current financials and negative cash flow pose substantial downside risk.
FCEL trades at $17.245, down 6.1% over 24 hours, with a neutral technical signal and bearish moving averages. The company reported a net loss of $187.90M on $158.16M revenue in 2025, with negative gross and net income margins. Recent news highlights a securities class action lawsuit filed against the company, alleging misleading disclosures between June and September 2026.
The outlook remains challenging due to persistent losses and legal risks, though analyst consensus suggests a $21.57 price target with 40% buy ratings. Key risks include cash burn, execution hurdles, and the ongoing lawsuit, while potential upside hinges on operational improvements and sector momentum.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →